Effect of sequential treatments with alendronate, parathyroid hormone (1–34) and raloxifene on cortical bone mass and strength in ovariectomized rats-Reference-Cited by-同舟云学术

Effect of sequential treatments with alendronate, parathyroid hormone (1–34) and raloxifene on cortical bone mass and strength in ovariectomized rats

Published:2014-10 Issue: Volume:67 Page:257-268
ISSN:8756-3282
Container-title:Bone
language:en
Short-container-title:Bone

Author:

Amugongo Sarah K.,Yao Wei,Jia Junjing,Dai Weiwei,Lay Yu-An E.,Jiang Li,Harvey Danielle,Zimmermann Elizabeth A.,Schaible Eric,Dave Neil,Ritchie Robert O.,Kimmel Donald B.,Lane Nancy E.

Publisher

Elsevier BV

Subject

Histology,Physiology,Endocrinology, Diabetes and Metabolism

Reference115 articles.

1. Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010;Salomon;Lancet,2012

2. Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010;Wang;Lancet,2012

3. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia;Evans;Endocrinology,1996

4. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats;Ominsky;J Bone Miner Res,2008

5. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats;Seedor;J Bone Miner Res,1991

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osteoblastgenic and Osteogenic Effects of KY-273 with CDK8/19 Inhibitory Activity in Bone Marrow Mesenchymal Stem Cells and Female Rats;Biological and Pharmaceutical Bulletin;2024-03-21

2. Osteogenic Effects of KY-054, a Novel Coumarin Derivative on Femur Cortical Bone in Ovariectomized Female Rats;Biological and Pharmaceutical Bulletin;2023-10-01

3. Maintenance of increased bone mass after PTH withdrawal by sequential medicarpin treatment via augmentation of cAMP‐PKA pathway;Journal of Cellular Biochemistry;2022-08-12

4. Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use;Bone;2022-02

5. Bisphosphonate‐enoxacin inhibit osteoclast formation and function by abrogating RANKL‐induced JNK signalling pathways during osteoporosis treatment;Journal of Cellular and Molecular Medicine;2021-10-15